$RVTY

Bernstein reiterated a Market Perform rating on Revvity (NYSE:RVTY) with a $160 price target ahead of its investor day. The stock trades at $158.25, but is considered overvalued. Bernstein expects AI in drug discovery to be the focus. Revvity reported Q3 2026 earnings of $1.37 per share on $729M revenue, beating estimates. BofA and Stifel raised their price targets to $185 and $177, respectively, citing strong performance and AI demand.

Revvity (RVTY) saw $25.3M net ETF outflows on Nov. 4, driven by DFSV's $27M reduction. 25 ETFs bought while 7 sold, but sellers had larger positions. RVTY operates in healthcare diagnostics, with $16.8B market cap, $2.94B TTM revenue, and 56.28% YTD gain. P/E is 66.77, P/B 2.32, and P/S 5.75.

JP Morgan kept its Neutral rating on Revvity but raised its price target to $160 from $155, citing a 3.2% increase. The new target suggests a 2.1% downside from the Nov 3 close of $163.48. Recent analyst notes on Revvity have price targets ranging from $172 to $185.

TD Cowen reiterated its Buy rating on Revvity and increased its price target to $185 from $175, suggesting a 13.2% upside from the Nov 3 close of $163.48. Recent analyst price targets for Revvity range from $172 to $180.

Barclays kept its Equal-Weight rating on Revvity but raised its price target to $175 from $160, suggesting a 7% upside from the recent close. Other analysts' targets range from $160 to $180.

RBC Capital kept its Sector Perform rating on Revvity but raised its price target to $172 from $135, a 27.4% increase. This implies a 5.2% upside from the Nov 3 close of $163.48. Recent analyst price targets for Revvity range from $160 to $180.

Regal Rexnord (RRX) rose 10.6% after beating Q3 2026 estimates and exploring a business sale. Camping World (CWH) fell 5.2% with a Q3 loss. Advanced Energy (AEIS) gained 9.8% on record revenue. Shopify (SHOP) dropped 9.4% with GMV below forecasts. Revvity (RVTY) increased 12.2% after raising full-year guidance.

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

Revvity shares rose 7% after raising its full-year EPS guidance to $5.40-$5.45. Pfizer reported Q3 earnings of 87 cents per share on $16.58B revenue, meeting expectations. Zebra Technologies fell 6% despite beating Q3 estimates, with lower free cash flow guidance. Gartner dropped 6% despite strong Q3 results and upbeat guidance. Yum Brands gained 1% after Q3 earnings beat estimates. Palantir fell 8% despite topping Q3 estimates and strong revenue growth.

Revvity reported Q3 2026 pro forma revenue of $729M, up 7% YoY, with adjusted EPS of $0.60. The company raised full-year guidance, forecasting $2.86B in 2026 revenue. CEO Prahlad Singh highlighted strong performance and growth momentum. Investor Day is scheduled for November 13, 2026.